396 related articles for article (PubMed ID: 31167790)
1. A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH.
Ueda M; Okada M; Mizuguchi M; Kluve-Beckerman B; Kanenawa K; Isoguchi A; Misumi Y; Tasaki M; Ueda A; Kanai A; Sasaki R; Masuda T; Inoue Y; Nomura T; Shinriki S; Shuto T; Kai H; Yamashita T; Matsui H; Benson MD; Ando Y
J Biol Chem; 2019 Jul; 294(29):11259-11275. PubMed ID: 31167790
[TBL] [Abstract][Full Text] [Related]
2. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.
Saelices L; Chung K; Lee JH; Cohn W; Whitelegge JP; Benson MD; Eisenberg DS
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6741-E6750. PubMed ID: 29954863
[TBL] [Abstract][Full Text] [Related]
3. Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis.
Schmidt M; Wiese S; Adak V; Engler J; Agarwal S; Fritz G; Westermark P; Zacharias M; Fändrich M
Nat Commun; 2019 Nov; 10(1):5008. PubMed ID: 31676763
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial screening for therapeutics in ATTRv amyloidosis identifies naphthoquinone analogues as TTR-selective amyloid disruptors.
Sasaki R; Suico MA; Chosa K; Teranishi Y; Sato T; Kagami A; Kotani S; Kato H; Hitora Y; Tsukamoto S; Yamashita T; Yokoyama T; Mizuguchi M; Kai H; Shuto T
J Pharmacol Sci; 2023 Jan; 151(1):54-62. PubMed ID: 36522123
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for transthyretin amyloid formation in vitreous body of the eye.
Iakovleva I; Hall M; Oelker M; Sandblad L; Anan I; Sauer-Eriksson AE
Nat Commun; 2021 Dec; 12(1):7141. PubMed ID: 34880242
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activation triggers transthyretin amyloidogenesis
Mangione PP; Verona G; Corazza A; Marcoux J; Canetti D; Giorgetti S; Raimondi S; Stoppini M; Esposito M; Relini A; Canale C; Valli M; Marchese L; Faravelli G; Obici L; Hawkins PN; Taylor GW; Gillmore JD; Pepys MB; Bellotti V
J Biol Chem; 2018 Sep; 293(37):14192-14199. PubMed ID: 30018138
[TBL] [Abstract][Full Text] [Related]
7. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis.
Pinheiro F; Varejão N; Esperante S; Santos J; Velázquez-Campoy A; Reverter D; Pallarès I; Ventura S
FEBS J; 2021 Jan; 288(1):310-324. PubMed ID: 32324953
[TBL] [Abstract][Full Text] [Related]
8. Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.
Klimtchuk ES; Prokaeva T; Frame NM; Abdullahi HA; Spencer B; Dasari S; Cui H; Berk JL; Kurtin PJ; Connors LH; Gursky O
Proc Natl Acad Sci U S A; 2018 Jul; 115(28):E6428-E6436. PubMed ID: 29941560
[TBL] [Abstract][Full Text] [Related]
9. Transthyretin: Its function and amyloid formation.
Ueda M
Neurochem Int; 2022 May; 155():105313. PubMed ID: 35218869
[TBL] [Abstract][Full Text] [Related]
10. Transthyretin forms amyloid fibrils at physiological pH with ultrasonication.
Misumi Y; Ueda M; Fujimori H; Shinriki S; Meng W; Kim J; Saito S; Obayashi K; Uchino M; Ando Y
Amyloid; 2008 Dec; 15(4):234-9. PubMed ID: 19065294
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
Lashuel HA; Lai Z; Kelly JW
Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
[TBL] [Abstract][Full Text] [Related]
12. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.
Higaki JN; Chakrabartty A; Galant NJ; Hadley KC; Hammerson B; Nijjar T; Torres R; Tapia JR; Salmans J; Barbour R; Tam SJ; Flanagan K; Zago W; Kinney GG
Amyloid; 2016 Jun; 23(2):86-97. PubMed ID: 26981744
[TBL] [Abstract][Full Text] [Related]
13. A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis).
Gonzalez-Duarte A; Ulloa-Aguirre A
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884963
[TBL] [Abstract][Full Text] [Related]
14. Transthyretin Anti-Amyloidogenic and Fibril Disrupting Activities of
Eze FN; Ingkaninan K; Prapunpoj P
Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31835306
[TBL] [Abstract][Full Text] [Related]
15. Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis.
Slamova I; Adib R; Ellmerich S; Golos MR; Gilbertson JA; Botcher N; Canetti D; Taylor GW; Rendell N; Tennent GA; Verona G; Porcari R; Mangione PP; Gillmore JD; Pepys MB; Bellotti V; Hawkins PN; Al-Shawi R; Simons JP
Nat Commun; 2021 Dec; 12(1):7112. PubMed ID: 34876572
[TBL] [Abstract][Full Text] [Related]
16. Clusterin regulates transthyretin amyloidosis.
Lee KW; Lee DH; Son H; Kim YS; Park JY; Roh GS; Kim HJ; Kang SS; Cho GJ; Choi WS
Biochem Biophys Res Commun; 2009 Oct; 388(2):256-60. PubMed ID: 19664600
[TBL] [Abstract][Full Text] [Related]
17. Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis.
Morfino P; Aimo A; Panichella G; Rapezzi C; Emdin M
Heart Fail Rev; 2022 Nov; 27(6):2187-2200. PubMed ID: 35386059
[TBL] [Abstract][Full Text] [Related]
18. Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy.
Taguchi K; Jono H; Kugimiya-Taguchi T; Nagao S; Su Y; Yamasaki K; Mizuguchi M; Maruyama T; Ando Y; Otagiri M
Life Sci; 2013 Dec; 93(25-26):1017-22. PubMed ID: 24211615
[TBL] [Abstract][Full Text] [Related]
19. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition.
Suhr OB; Lundgren E; Westermark P
J Intern Med; 2017 Apr; 281(4):337-347. PubMed ID: 28093848
[TBL] [Abstract][Full Text] [Related]
20. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
Lai Z; Colón W; Kelly JW
Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]